About: The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation
Creator	Navarro, David Balaguer-Roselló, Aitana Carretero, Carlos Montoro, Juan Salavert, Miguel Sanz, Guillermo Sanz, Jaime Aznar, Carla Guerreiro, Manuel Lorenzo, Ignacio Sanz, Rosa Sanz, Miguel Dolores Gómez, María María González-Barberá, Eva Piñana, Joséluis
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: There is a lack of studies comparing clinical outcomes among retrospective versus prospective cohorts of allogeneic stem cell transplant (allo-HCT) recipients with community acquired respiratory virus (CARV) infections. METHODS: We compare outcomes in two consecutive cohorts of allo-HCT recipients with CARV infections. The retrospective cohort included 63 allo-HCT recipients with 108 CARV infections from January 2013 to April 2016 who were screened and managed following standard clinical practice based on influenza and respiratory syncytial virus rapid antigen detection methods. The prospective cohort was comprised of 144 consecutive recipients with 297 CARV episodes included in a prospective interventional clinical surveillance program (ProClinCarvSur-P) based on syndromic multiplex PCR as first-line test from May 2016 to December 2018 at a single transplant center. RESULTS: CARV infections in the retrospective cohort showed more severe clinical features at the time of diagnosis compared to the prospective cohort (fever 83% vs. 57%, hospital admission 69% vs. 28% and lower respiratory tract 58% vs. 31%, respectively, p ≤ 0.002 for all comparisons). Antiviral therapy was more commonly prescribed in the prospective cohort (69 vs. 43 treated CARV episodes), particularly at the upper respiratory tract disease stage (34 vs. 12 treated CARV episodes). Three-month all-cause mortality was significantly higher in the retrospective cohort (n = 23, 37% vs. n = 10, 7%, p < 0.0001). Multivariate logistic regression analysis showed that recipients included in ProClinCarvSur-P had lower mortality rate [odds ratio 0.31, 95% confidence interval 0.12–0.7, p = 0.01]. CONCLUSION: This study report on outcome differences when reporting retrospective vs. prospective CARV infections after allo-HCT. Recipients included in a ProClinCarvSur-P had lower mortality.
has issue date	2020-01-20(xsd:dateTime)
bibo:doi	10.1016/j.jinf.2019.12.022
bibo:pmid	31972212
has license	no-cc
sha1sum (hex)	a2785a24434a55b973d8220ec9ce26427ff6af22
schema:url	https://doi.org/10.1016/j.jinf.2019.12.022
resource representing a document's title	The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation
has PubMed Central identifier	PMC7112613
has PubMed identifier	31972212
schema:publication	J Infect
resource representing a document's body	covid:a2785a24434a55b973d8220ec9ce26427ff6af22#body_text
is schema:about of	named entity 'COMMUNITY' named entity 'CLINICAL BENEFIT' named entity 'PROSPECTIVE' named entity 'SURVEILLANCE PROGRAM' named entity 'CLINICAL' named entity 'RESPIRATORY VIRUS' named entity 'ACQUIRED' named entity 'ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION' named entity 'virus' named entity 'infection' named entity 'all-cause mortality' named entity 'HPiV' named entity 'high-risk' named entity 'conditioning regimen' named entity 'viruses' named entity 'Mann-Whitney U test' named entity 'chest X-ray' named entity 'virus' named entity 'relapse' named entity 'retrospective cohort' named entity 'RT-PCR' named entity 'RSV' named entity 'influenza' named entity 'pharyngitis' named entity 'outpatient clinic' named entity 'general population' named entity 'prospective cohort' named entity 'antigen' named entity 'influenza' named entity 'mortality rates' named entity 'odds ratio' named entity '21%' named entity 'immunosuppressant drugs' named entity 'PCR test' named entity 'airflow obstruction' named entity 'respiratory symptoms' named entity 'ISI' named entity 'multivariate analyses' named entity 'influenza' named entity 'mortality rate' named entity 'hemorrhage' named entity 'immunochromatographic' named entity 'URD' named entity 'all-cause mortality' named entity 'nasopharyngeal swabs' named entity 'RFs' named entity 'Immunodeficiency' named entity '2.1' named entity 'StCP' named entity 'RSV' named entity 'prospective cohort' named entity 'multivariate analysis' named entity 'stem cell' named entity 'respiratory symptoms' named entity 'influenza vaccination' named entity 'StCP' named entity 'selection bias' named entity 'stem cell' named entity 'RSV' named entity 'HPiV' named entity 'follow-up' named entity 'prospective cohort' named entity 'antiviral' named entity 'multiplex PCR' named entity 'DNA array' named entity '21%' named entity 'relapse'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software